Geode Capital Management’s Windtree Therapeutics WINT Stock Holding History

Geode Capital Management’s Portfolio WINT Stock Details WINT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,183	Closed	-$20.7K	–	4511
2024 Q4	$20.7K	Buy	+1,183	New	+$37.5K	﹤0.01%	4380
2024 Q2	–	Sell	-16	Closed	-$4.95K	–	4628
2024 Q1	$4.95K	Hold	16	–	–	﹤0.01%	4585
2023 Q4	$10.2K	Hold	16	–	–	﹤0.01%	4587
2023 Q3	$13.7K	Buy	+16	New	+$17.7K	﹤0.01%	4685
2023 Q1	–	Sell	-4	Closed	-$26K	–	4831
2022 Q4	$26K	Hold	4	–	–	﹤0.01%	4728
2022 Q3	$47K	Hold	4	–	–	﹤0.01%	4778
2022 Q2	$66K	Hold	4	–	–	﹤0.01%	4710
2022 Q1	$180K	Hold	4	–	–	﹤0.01%	4429
2021 Q4	$254K	Hold	4	–	–	﹤0.01%	4372
2021 Q3	$327K	Buy	4 +2	+100%	+$170K	﹤0.01%	4228
2021 Q2	$158K	Buy	+2	New	+$195K	﹤0.01%	4425

Other funds holding WINT

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Geode Capital Management's WINT Position: Q1 2025 in Review

Geode Capital Management sold out of Windtree Therapeutics (WINT) in Q1 2025, closing a stake of 1,183 shares — an estimated $20.7K sold.

Geode Capital Management first reported a position in WINT in Q2 2021 and held it in 11 quarters. The position peaked at $327K in Q3 2021. 5 funds tracked by Wall St. Rank hold WINT as of Q1 2025.

Geode Capital Management reported no remaining Windtree Therapeutics position as of Q1 2025 after selling out during the quarter.
Geode Capital Management sold 1,183 Windtree Therapeutics shares in Q1 2025, an estimated $20.7K.
Geode Capital Management first reported a position in Windtree Therapeutics in Q2 2021 and held it in 11 quarters.
Geode Capital Management's Windtree Therapeutics position peaked at $327K in Q3 2021.
5 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2025.

Based on Geode Capital Management's 13F filing for Q1 2025, filed 13 May 2025.